← 프로그램 목록
Phase 3Recruiting

Bendamustine Hydrochloride

AbbVie

비교

Bendamustine Hydrochloride(AbbVie)은 FRα 표적 치료제로, Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia 영역에서 개발·상용화 중입니다. 작용기전: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 73% (ClinicalTrials.gov NCT01596621). 차별점: unique organ involvement patterns and generally poorer prognosis.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 9일 (5일 전)PK/독성 2026년 7월 9일 (5일 전)

FRα

Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia

Recruiting

Technology

구조모아 · MMAE (auristatin)

CAR-T Therapy in Hematological Malignancies: A Systematic Review

vedotin combined with bendamustine and rituxima

unique organ involvement patterns and generally poorer prognosis

Mechanism of Action

Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring

cytokine release syndrome may have facilitated T-cell-mediated orbital inflammation, while bendamustine-induced lymp

apoptosis in breast cancer cell line by the powerful alkylating agent bendamustine and insights into its molecular mechanisms

biomarker data at diagnosis were included in the survival analysis

Downregulation of major antioxidant enzymes (SOD, CAT, GPx1, GST; p < 0

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 69건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 2, Phase 3 · Phase 2
  • Status: Recruiting · Completed · Terminated
  • 주요 endpoint: Arm A1 vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30) · Arm A1 vs Arm B: Number of Participants with Progression-free survival (PFS) · Arm A1 vs Arm B: Overall Survival (OS) · Arm A1 vs Arm B: Rate of Minimal Residual Disease (MRD) Negativity Rate · Arm A1 vs Arm B: Change from Baseline in Physical Functioning (PF) According to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer (EORTC QLQ-C30)
  • 등록된 결과: ORR 73%
  • 핵심: The primary objective of the study is to determine the overall response rate (ORR), which includes complete response (CR…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Bendamustine Hydrochloride은 어떤 치료제인가요?
Bendamustine Hydrochloride(AbbVie)은 FRα 표적 항체로, Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Bendamustine Hydrochloride의 임상 단계는?
Bendamustine Hydrochloride의 현재 단계는 Phase 3입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.